Identity
- Trade Name
- CA19-9 (121SLE) Mouse Monoclonal Antibody FDA UDI
- Generic Name
- Cancer antigen 19-9 (CA19-9) GI IVD, antibody FDA UDI
- Model / Reference
- 399M-18 FDA UDI
Identifiers
- Primary DI / UDI-DI
- 00841683141037 FDA UDI
- FDA Product Code
- NJT FDA UDI
- GMDN Term
- Cancer antigen 19-9 (CA19-9) GI IVD, antibody FDA UDI
Classification
- Device Class
- Class I FDA UDI
- Regulation Number
- 864.1860 FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
No
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
Yes
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Cancer antigen 19-9 (CA19-9) GI IVD, antibody
CA19-9 (121SLE) Mouse Monoclonal Antibody by Cell Marque Corporation — Class I — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Cancer antigen 19-9 (CA19-9) GI IVD, antibody.
- CA 19-9 — BIOCARE MEDICAL, LLC · Class I
- CA 19-9 — BIOCARE MEDICAL, LLC · Class I
- CA 19-9 — BIOCARE MEDICAL, LLC · Class I
- BOND™ — Leica Biosystems Newcastle, Limited · Class I
- ANTI-CA19-9 — Biogenex Laboratories, Inc. · Class I
- Anti-CA19-9 — Biogenex Laboratories, Inc. · Class I
- Mono Mo A-Hu CA 19-9 Cl 1116-NS-19-9 — Agilent Technologies Inc. · Class I
- Genemed® — Sakura Finetek USA, Inc · Class I
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class I | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Cell Marque Corporation
Sources (1)
- FDA UDI 4dd3579f-e784-466c-b386-5d4411f708ac 33 fields · synced May 29, 2026